Anticonvulsant Hypersensitivity Syndrome

Archives of Internal Medicine

Volumn 155, Issue 21, 1995, Pages 2285-2290

  Vittorio, Carmela C ^a   Muglia, Jennie J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBAMAZEPINE; CORTICOSTEROID; CYTOCHROME P450; DIPHENHYDRAMINE; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PHENOBARBITAL; PHENYTOIN; PREDNISONE;

ANTICONVULSANT THERAPY; CLINICAL FEATURE; CONVULSION; CORTICOSTEROID THERAPY; DOSE LIVER FUNCTION RELATION; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOPATHOGENESIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SYNDROME; TOPICAL DRUG ADMINISTRATION;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CASE REPORT; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMAN; LYMPHATIC DISEASES; MALE; PHENOBARBITAL; PHENYTOIN; PROGNOSIS; SYNDROME;

EID: 0028793442     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1995.00430210033005     Document Type: Article

References (62)

1. Silber IB, Epstein JW. The treatment of chorea with phenylethylhydantoin: a study of 28 cases. Arch Pediatr. 1934;51:373-382.
2. Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol. 1991;127:1361-4.
3. Chaiken BH, Goldberg BI, Segal JP. Dilantin hypersensitivity: report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. N Engl J Med. 1950;242:897-898.
4. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Speilberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med. 1991;91: 631-634.
5. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol. 1988;18:721-741.
6. Merritt HH, Putnam TJ. Sodium diphenylhydantoin in the treatment of convulsive disorders. JAMA. 1938;111:1068-1073.
7. Gropper AL. Diphenylhydantoin sensitivity: report of fatal case with hepatitis and exfoliative dermatitis. N Engl J Med. 1956;254:522-523.
8. Siegal S, Berkowitz J. Diphenylhydantoin (Dilantin) hypersensitivity with infectious mononucleosis-like syndrome and jaundice. J Allergy Clin Immunol. 1961;32:447-451.
9. Holland P, Mauer AM. Diphenylhydantoin-induced hypersensitivity reaction. J Pediatr. 1965; 66:322-332.
10. Robinson HM Jr, Stone JH. Exanthem due to diphenylhydantoin therapy. Arch Dermatol. 1970; 101:462-465.
11. Weeden AP. Diphenylhydantoin sensitivity: a syndrome resembling infectious mononucleosis with a morbilliform rash and cholestatic hepatitis. Aust N Z J Med. 1975;5:561-563.
12. Stanley J, Fallon-Pellicci V. Phenytoin hypersensitivity reaction. Arch Dermatol. 1978;114:1350-1353.
13. Haruda H. Phenytoin hypersensitivity: 38 cases. Neurology. 1979;29:1480-1485.
14. Josephs SH, Rothman SJ, Buckley RH. Phenytoin hypersensitivity. J Allergy Clin Immunol. 1980;66:166-172.
15. Rapp RP, Newton JA, Young B, Tibbs PA. Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery. 1983;272-275.
16. Tomsick RS. The phenytoin syndrome. Cutis. 1983;32:535-541.
17. Knutsen AP, Anderson J, Satayariboon S, Slavin RG. Immunologic aspects of phenobarbital hypersensitivity. J Pediatr. 1984;105:558-563.
18. Flowers FP, Araujo OE. Phenytoin hypersensitivity syndrome. J Emerg Med. 1987;5:103-108.
19. Prosser TR, Lander RD. Phenytoin-induced hypersensitivity reactions. Clin Pharmacokinet. 1987; 6:728-734.
20. Ray-Chaudhuri K, Pye IF, Boggild, M. Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma and renal failure. Neurology. 1989;39:436-438.
21. Romaguera C, Grimalt F, Vilaplana J, Azon A. Erythroderma from carbamazepine. Contact Dermatitis. 1989:20:304-305.
22. Chang, DK, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol. 1992;12:329-337.
23. Gaffey CM, Chun B, Harvey JC, Manz HJ. Phenytoin-induced systemic granulomatous vasculitis. Arch Pathol Lab Med. 1986;110:131-135.
24. Dhar GJ, Ahamed PN, Pierach CA, Howard RB. Diphenylhydantoin-induced hepatic necrosis. Postgrad Med. 1974;56:128-134.
25. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
26. Taylor JW, Stein MN, Murphy MJ, Mitros FA. Cholestatic liver dysfunction after long-term phenytoin therapy. Arch Neurol. 1984;41:500-501.
27. Pezzimenti JF, Hahn AL. Anicteric hepatitis induced by diphenylhydantoin. Arch Intern Med. 1970;125:118-120.
28. Schmidt D, Kluge W. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. Epilepsia. 1983;24:440-443.
29. Anderson VM, Bauer HM, Kelly AP. Mucocutaneous lymph node syndrome in an adult receiving diphenylhydantoin. Cutis. 1979;23:493-498.
30. Saltzman SL, Ackerman LV. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer. 1959;12:164-182.
31. Choovivathanavanich P, Wallace EM, Scaglione PR. Pseudolymphoma induced by diphenylhydantoin. J Pediatr. 1970;76:621-623.
32. Charlesworth EN. Phenytoin-induced pseudolymphoma syndrome. Arch Dermatol. 1977;113: 477-480.
33. Schwinghammer TL, Howrie DL. Phenytoin-induced lymphadenopathy. Drug Intell Clin Pharm. 1983;17:460-462.
34. Gams RA, Neal JA, Conrad FG. Hydantoin induced pseudo-pseudolymphoma. Ann Intern Med. 1968;69:557-558.
35. Harinasula U, Zimmerman HJ. Diphenylhydantoin sodium hepatitis. JAMA. 1968;203:1015-1018.
36. Parker WA, Shearer CA. Phenytoin hepatotoxicity: a case report and review. Neurology. 1979; 29:175-178.
37. Ting S, Maj MC, Dunsky EH. Diphenylhydantoin-induced hepatitis. Ann Allergy. 1982;48:331-332.
38. Howard PA, Engen PL, Dunn Ml. Phenytoin hypersensitivity syndrome: a case report. Ann Pharmacother. 1991;25:929-932.
39. Smythe MA, Umstead GS. Phenytoin hepatotoxicity: a review of the literature. Ann Pharmacother. 1989;23:13-17.
40. Brown M, Schubert T. Phenytoin hypersensitivity hepatitis and mononucleosis syndrome. J Clin Gastroenterol. 1986;8:469-477.
41. Choen BL, Bovasso GT. Leukopenia as an unusual component of diphenylhydantoin hypersensitivity: a case with pruritus, rash, fever, lymphadenopathy, but low leucocyte count. Clin Pediatr (Phila). 1973;12:622-623.
42. Fruchter L, Laptook A. Diphenylhydantoin hypersensitivity reaction associated with pulmonary infiltrates and hypereosinophilia. Ann Allergy. 1981;47:453-454.
43. Mahatma M, Haponik EK, Nelson S, Lopez A, Summer WR. Phenytoin-induced acute respiratory failure with pulmonary eosinophilia. Am J Med. 1989; 87:93-94.
44. Josephs SH, Rothman SJ, Buckley RH. Phenytoin hypersensitivity. J Allergy Clin Immunol. 1980;66:166-172.
45. Michael JR, Mitch WE. Reversible renal failure and myositis caused by phenytoin hypersensitivity. JAMA. 1976;236:2773-2775.
46. Sheth KJ, Casper JJT, Good TA. Interstitial nephritis due to phenytoin hypersensitivity. J Pediatr. 1977;91:438-441.
47. Harney J, Glasberg MR. Myopathy and hypersensitivity to phenytoin. Neurology. 1983;33: 790-791.
48. Engel JN, Mellul VG, Goodman DB. Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med. 1986;81:928-930.
49. Guerra IC, Fawcett WA IV, Redmon AH, Lawrence EC, Rosenblatt HM, Shearer WT. Permanent intrinsic B cell immunodeficiency caused by phenytoin hypersensitivity. J Allergy Clin Immunol. 1986;77:603-607.
50. Gleichmann H. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol. 1981;18:203-211.
51. Robinson DS, MacDonald MG, Hobin FP. Sodium diphenylhydantoin reaction with evidence of circulating antibodies. JAMA. 1965;192:171-172.
52. Kleckner HB, Yakulis V, Heller P. Severe hypersensitivity to diphenylhydantoin with circulating antibodies to the drug. Ann Intern Med. 1975; 83:522-523.
53. Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics. 1992:23:272-275.
54. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an auto-antibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol. 1992;33:183-186.
55. Spielberg SP, Gordon GB, Blake DA, Mellits DE, Bross DS. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther. 1981;217:386-389.
56. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med. 1981; 305:722-727.
57. Reents SB, Luginbuhl WE, Davis SM. Phenytoin-carbamazepine cross-sensitivity. Ann Pharmacother. 1989;23:235-236.
58. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol. 1991;32:741-749.
59. Ebeid MR, Feldman S, Parks B, Parker P. An atypical hypersensitivity reaction. Hosp Pract (Off Ed). 1989;24:57-62.
60. Lisker-Melman M, Hoofnagle JH. Phenytoin hepatotoxicity masked by corticosteroids. Arch Intern Med. 1989;149:1196-1197.
61. Kahn HD, Faguet G, Agee JF, Middleton III HM. Drug-induced liver injury: in vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch Intern Med. 1984;144:1677-1679.
62. Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983;61:889-893.